BioCryst Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

BioCryst Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 66.2% bzw. 16.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 65.8% pro Jahr wachsen soll.

Wichtige Informationen

66.2%

Wachstumsrate der Gewinne

65.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	16.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	07 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

Jun 08

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks

Aug 18

BioCryst Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

BioCryst Pharmaceuticals: Waiting For Clarity

Jul 25

BioCryst: A Prudent Diversification

Jun 24

BioCryst: BCX9930's Hiccup Affects The Entire Company

Apr 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BCRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	580	55	165	N/A	7
12/31/2025	486	-74	99	-4	9
12/31/2024	401	-128	29	5	10
3/31/2024	355	-209	-104	-101	N/A
12/31/2023	331	-227	-97	-95	N/A
9/30/2023	318	-236	-112	-110	N/A
6/30/2023	307	-243	-124	-123	N/A
3/31/2023	290	-226	-133	-132	N/A
12/31/2022	271	-247	-163	-162	N/A
9/30/2022	238	-193	-172	-170	N/A
6/30/2022	204	-210	-163	-161	N/A
3/31/2022	188	-194	-162	-159	N/A
12/31/2021	157	-184	-145	-142	N/A
9/30/2021	114	-227	-154	-152	N/A
6/30/2021	79	-214	-168	-167	N/A
3/31/2021	32	-209	-173	-173	N/A
12/31/2020	18	-183	-136	-135	N/A
9/30/2020	54	-125	-103	-103	N/A
6/30/2020	49	-116	-93	-92	N/A
3/31/2020	48	-115	-86	-86	N/A
12/31/2019	49	-109	-90	-90	N/A
9/30/2019	12	-134	-103	-103	N/A
6/30/2019	12	-126	-111	-111	N/A
3/31/2019	23	-107	-100	-100	N/A
12/31/2018	21	-101	-93	-93	N/A
9/30/2018	22	-93	-79	-79	N/A
6/30/2018	29	-79	-57	-56	N/A
3/31/2018	20	-77	-53	-52	N/A
12/31/2017	25	-66	N/A	-41	N/A
9/30/2017	30	-51	N/A	-36	N/A
6/30/2017	29	-47	N/A	-42	N/A
3/31/2017	31	-47	N/A	-43	N/A
12/31/2016	26	-55	N/A	-53	N/A
9/30/2016	22	-69	N/A	-62	N/A
6/30/2016	25	-72	N/A	-58	N/A
3/31/2016	46	-51	N/A	-28	N/A
12/31/2015	48	-43	N/A	-13	N/A
9/30/2015	49	-37	N/A	-12	N/A
6/30/2015	41	-31	N/A	-8	N/A
3/31/2015	17	-50	N/A	-33	N/A
12/31/2014	14	-45	N/A	-39	N/A
9/30/2014	19	-39	N/A	-29	N/A
6/30/2014	18	-38	N/A	-28	N/A
3/31/2014	17	-36	N/A	-24	N/A
12/31/2013	17	-30	N/A	-27	N/A
9/30/2013	11	-36	N/A	-29	N/A
6/30/2013	14	-37	N/A	-33	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BCRX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: BCRX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: BCRX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: BCRXDie Einnahmen des Unternehmens (16.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: BCRXDie Einnahmen des Unternehmens (16.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BCRX in 3 Jahren voraussichtlich hoch sein wird

BioCryst Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.60 loss

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Price target decreased by 13% to US$12.20

Forecast breakeven date pushed back to 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Recent updates

Senior VP recently bought US$202k worth of stock

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Consensus EPS estimates upgraded to US$0.60 loss

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Price target decreased by 13% to US$12.20

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Full year 2023 earnings: EPS misses analyst expectations

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Forecast breakeven date pushed back to 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

Price target decreased by 7.3% to US$14.09

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

New minor risk - Shareholder dilution

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.23 loss in 3Q 2022)

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Consensus EPS estimates fall by 16%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CEO, President & Executive Director exercised options to buy US$264k worth of stock.

Consensus EPS estimates fall by 13%

Price target decreased by 7.5% to US$15.45

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

CEO, President & Executive Director exercised options and sold US$493k worth of stock

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

Forecast to breakeven in 2025

CEO, President & Executive Director exercised options and sold US$3.4m worth of stock

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

Chief Discovery Officer exercised options and sold US$393k worth of stock

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

BioCryst Pharmaceuticals promotes Sheridan to development chief

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

BioCryst wins FDA’s Orphan Drug status for bone disorder therapy

Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients

BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M

Price target increased to US$18.60

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks